RESEARCH
ONGOING CLINICAL TRIALS
/ SECOND-LINE STUDIES
Medimmune D4190C00022
A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects with Unresectable Hepatocellular Carcinoma.

Population: Immunotherapy-naive subjects with unresectable HCC who have progressed on, are intolerant of, or refused sorafenib-based therapy.


Phase I ADP-0033-001 Second line
A PHASE I OPEN LABEL, CLINICAL TRIAL EVALUATING THE SAFETY AND ANTI-TUMOR ACTIVITY OF AUTOLOGOUS T CELLS EXPRESSING ENHANCED TCRS SPECIFIC FOR ALPHA-FETOPROTEIN (AFPC332T) IN HLA-A2 POSITIVE SUBJECTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)

A Phase 1/2 open-label, multi-center, safety, preliminary efficacy and pharmacokinetic (PK) study of isatuximab (SAR650984) in combination with atezolizumab or isatuximab alone in patients with advanced malignancies
Safety, preliminary efficacy and PK of isatuximab (SAR650984) alone or in combination with atezolizumab in patients with advanced malignancies